Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL2568782 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9568279 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL5747359 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL3207413 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL888275 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9037829 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9526391 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9525441 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL2571706 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 | |
| Chloroform SCHEMBL9528226 | 1.00 | LMNA (0.57) | LMNATSHRALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106631709-A | Hydroxytyrosol extraction and nitration method | 中国林业科学研究院林产化学工业研究所 | 2017-05-10 | — | — | CN | claimed |
| CN-102372721-A | Preparation method for magnolin | SUZHOU BAOZETANG MEDICAL TECH | 2012-03-14 | — | — | CN | claimed |
| EP-4349331-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | Kyoto Pharmaceutical University (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-11633493-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-25 | — | — | US | disclosed |
| US-11584800-B2 | Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| WO-2022265069-A1 | ENZYME-STABILIZING AGENT FOR DETERGENTS | 花王株式会社 | 2022-12-22 | — | — | WO | disclosed |
| WO-2022255499-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | 学校法人京都薬科大学 | 2022-12-08 | — | — | WO | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
| US-11261261-B2 | — | — | 2022-03-01 | — | — | US | disclosed |
| WO-2021215522-A1 | LINDERAPYRONE, AND ANALOGUE THEREOF | 学校法人京都薬科大学 (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-10973924-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-0376114-A2 | 9-Dihydro-9-0-alkyldesmycosin derivatives | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0374095-A2 | Piperidine derivatives | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0275312-A1 | THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1988-07-27 | — | — | EP | disclosed |
| US-4631149-A | VIRICIDE, BACTERICIDE, ANTIBIOTIC, AND ANTITUMOR AGENT | UNIVERSITY OF ILLINOIS (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0133000-A2 | Antibiotics | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4331593-A | TRIPEPTIDE | SMITHWICK JR EDWARD L | 1982-05-25 | — | — | US | disclosed |
| EP-0050407-A1 | 3,5-Disubstituted-1,2,4-triazole compounds, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-04-28 | — | — | EP | disclosed |
| EP-0001684-B1 | TETRAPEPTIDES, METHODS FOR THEIR PREPARATION AND THEIR USE IN ANALGESIC COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4264491-A | OLIGOPEPTIDE | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633493-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | LMNA 150/4885TSHR 1899/4885ALDH1A1 439/4885 |
| US-10973924-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | LMNA 97/4885TSHR 2226/4885ALDH1A1 569/4885 |
| US-11261261-B2 | — | ERBB2, EGFR, H1-2 | LMNA 105/4885TSHR 1105/4885ALDH1A1 1166/4885 |
| US-11584800-B2 | Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate | ERBB2, EGFR, H1-2 | LMNA 160/4885TSHR 786/4885ALDH1A1 1073/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | LMNA 2692/4885TSHR 2286/4885ALDH1A1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.